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Abstract 
Background: Imported cases of multidrug resistant Plasmodium falciparum and treatment failure with artemisinin-
based regimens, although rare, have been described also in Western countries and their management is often chal-
lenging. This is also due to an inadequate knowledge and implementation of health prevention measures.
Case report: A complex case of imported malaria caused by Plasmodium vivax/P. falciparum isolates in a patient 
who was not taking chemoprophylaxis while he was travelling in Cambodia is reported in this article. After failures 
of artemisinin-based and both oral and intravenous quinine-based regimens, a multidrug resistant P. falciparum was 
detected. The patient was successfully treated with atovaquone–proguanil.
Conclusions: This experience highlights the importance of a careful management that should be based not only on 
the most up-to-date guidelines, but also on the awareness of a rapidly evolving scenario.
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Background
Imported cases of multidrug resistant (MDR) Plasmo-
dium falciparum and treatment failure with artemisinin-
based regimens, although rare, have been described also 
in Western countries and their management is often 
challenging [1, 2]. Even if uncommon, the possibility of 
imported infections by drug-resistant Plasmodium spp. 
should be considered, especially in travellers returning 
from highly endemic regions [3], where the most recent 
first-line artemisinin-based regimens are losing their 
effectiveness, also due to selective drug pressure [4, 5]. 
Moreover, the increasing accessibility to remote geo-
graphic areas of the world by do-it-yourself travellers not 
always keeps the pace with an adequate knowledge and 
implementation of health prevention measures. The fol-
lowing case illustrates these issues.
Case presentation
A 27-years old male Italian patient, carrying thalas-
semia trait, returned on November 22nd, 2015 from a 
4-week long pleasure trip to Cambodia, without taking 
any malaria chemoprophylaxis. This trip also included 
a 5-days trekking throughout the Pursat region. The day 
before his return, he had a rapid onset of fever up to 
39 °C preceded by chills, cough and diarrhoea. Due to the 
persistence of fever despite therapy with ciprofloxacin 
and paracetamol, he was admitted to the Clinic of Infec-
tious Diseases, Policlinico Hospital, Bari, on November 
25th. Upon admission he had dehydration, mild leucocy-
tosis (white blood cells 11.36 × 109/L), haemoglobin (Hb) 
13.3 g/dL, platelets (PLTs) 62 × 109/L, C-reactive protein 
(CRP) 64.8  mg/L. On suspicion of malaria, peripheral 
blood smears and molecular biology testing (multiplex 
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Real-Time PCR, Fast-Track Diagnostic) were performed, 
proving to be positive for P. falciparum and Plasmodium 
vivax, with a parasitaemia below 2%. A 3-day dihydroar-
temisinin–piperaquine regimen was initiated, with rapid 
defervescence and good clinical progress. After the end 
of treatment, blood smears resulted negative and the 
patient was discharged with prescription of 30 mg/day of 
primaquine for 14 days for radical cure.
On December 1th he was readmitted due to the reap-
pearance of fever in the previous 2  days. Primaquine 
treatment had not been initiated due to delayed supply 
of the drug which is not readily available in Italy. Labo-
ratory data showed anaemia (Hb 7.3  g/dL, requiring 
blood transfusion even in the absence of symptoms), 
thrombocytopaenia (PLTs 84  ×  109/L) and CRP eleva-
tion (40 mg/L). Peripheral blood smears were again posi-
tive for P. falciparum trophozoites; P. vivax gametocytes 
were also detected, as an expected biologic evolution 
without pathologic significance. This finding is consistent 
with missed start of primaquine. Therefore, a second-line 
therapy with oral quinine and doxycycline was started. A 
prompt clinical improvement was observed after 24 h; a 
7-day course of therapy was completed leading to nega-
tive blood smears. Primaquine administration was with-
held until the resolution of P. falciparum recrudescence 
and it was started on December 23rd shortly before 
hospital discharge. Indeed the patient was dismissed on 
December 24th with indication to complete a full 14-days 
course with weekly monitoring of complete blood count.
However, on January 18th the patient presented with 
fever and diarrhoea. After a few days of symptomatic 
home treatment with temporary benefit, he was read-
mitted showing thrombocytopaenia (PLTs 110 × 109/L), 
anaemia (Hb 9.2  g/dL) and CRP elevation (40.3  mg/L). 
Plasmodium falciparum trophozoites were detected on 
blood smears and therapy was initiated with intravenous 
quinine (loading dose of 20 mg/kg, followed by mainte-
nance dose of 10 mg/kg q8h for 7 days) at first and, sub-
sequently, with atovaquone/proguanil, thus obtaining the 
definitive clearance of the parasite and healing.
The resistance of the Plasmodium falciparum isolate 
infecting this patient to anti-malarial drugs was assessed 
by the evaluation of single nucleotide polymorphisms 
(SNPs) of six molecular gene markers (PfK13, Pfcrt, 
Pfmdr1, Pfdhfr, Pfdhps and PfCytB) linked to resistance 
to artemisinin derivatives, quinolines, antifolates–cyclo-
guanil and atovaquone.
Total DNA was extracted (PureLink Genomic DNA 
Kits-Invitrogen) from 200  µL of three patient’s blood 
specimens collected on November 26th, 2015 (first hospi-
tal admission), December 15th, 2015 (second admission) 
and January 29th, 2016 (third admission). The polymor-
phism of the P. falciparum K13-propeller gene, from 
codon 427 to codon 690, was assessed using the prim-
ers: ArtinnerF (GCCTTGTTGAAAGAAGCAGAA) and 
ArtouterR (CGCCATTTTCTCCTCCTGTA) and with 
PCR conditions described by Taylor et  al. [6]. Analysis 
of Pfcrt and Pfmdr1 genes was performed as previously 
reported [7, 8]. Different methods were used for the anal-
ysis of fragment of Pfdhfr gene spanning codons 51–108, 
Pfdhps domain (719  bp) and point mutation in PfCytB 
gene, according to Palmieri et al. [9], Menegon et al. [7] 
and Korsinczky et al. [10], respectively. All PCR products 
were sent to Eurofins Genomics Company (Germany) for 
sequencing, and sequences were compiled and analysed 
by Accelrys DS Gene software.
Analysis of polymorphisms of P. falciparum iso-
lates showed a pattern of multidrug resistance due to 
the presence of point mutations associated with qui-
noline (including amodiaquine), drug resistance in Pfcrt 
and Pfmdr1, and mutations correlated to sulfadoxine/
pyrimethamine resistance in Pfdhps and Pfdhfr genes 
(Table  1). In particular, in the Pfk13 gene was observed 
the presence of the mutation C580Y, which is an impor-
tant determinant of artemisinin resistance in P. falcipa-
rum population circulating in Southeast Asia [11, 12]. 
The absence of mutations at codons 258 and 268 of CytB 
gene indicated a sensitivity of the P. falciparum isolate to 
atovaquone and is consistent with the good response of 
the patient to atovaquone/proguanil administration.
Discussion
This report shows the serious consequences, both in 
terms of clinical impact and health-related expenses, of 
a rare and extended resistance pattern of P. falciparum 
strain. Indeed, the management of this patient was com-
plex; firstly, because he experienced three subsequent 
admissions, resulting in a prolonged hospitalization. Fur-
thermore, once malaria recrudescence was confirmed, 
pharmacological treatment was cumbersome in terms of 
drug supply, costs, safety profile and consequent need of 
strict monitoring. An additional issue was represented 
by molecular analysis, which required the expertise of 
the Italian National Institute of Health (ISS) since these 
assays are not routinely available. Lastly, patient’s anxiety 
regarding the course of the disease should also be taken 
into account.
A double recrudescence of P. falciparum in the same 
patient is a rare event to observe. Moreover, the chance of 
a recrudescence after a second-line treatment of oral qui-
nine plus doxycycline is very low [13]. Reasons for failure 
with this regimen may include a decrease in the sensitiv-
ity or an inadequate exposure to the drug caused by unu-
sual pharmacokinetics in an individual, scarce adherence 
to the prescribed regimen or poor quality of anti-malar-
ial drugs [14]. In this case, therefore, the concurrence of 
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Table 1 Analysis of polymorphisms of the P. falciparum isolates
Marker Pfcrt Pfmdr1 Pfk13 Pf Cytochrome b Pfdhfr Pfdhps
Codons 74 75 76 97 86 184 1034 1042 1246 580 258 268 51 59 108 436 437 540 581 613
Wild type
M N K H N Y S N D C I Y N C S S A K A A
atg aat aaa cac aat tat agt aat gat tgt aat tat aat tgt agc tct gct aaa gcg gcc
Mutant 
type
I E T Y Y F C D Y Y M F/S I R N A/F G E G S/T
att gaa aca tac tat ttt tgt gat tat tat atg ttt/tgt aat cgt aac gct/ttt ggt gaa ggg tcc/acc
Sample  
November 
26, 2015
I E T Y N F S N D Y I Y I R N S G E G A
att gaa aca tac aat ttt agt aat gat tat aat tat aat cgt aac tct ggt gaa ggg gcc
Sample 
December 
15, 2015
I E T Y N F S N D Y I Y I R N S G E G A
att gaa aca tac aat ttt agt aat gat tat aat tat aat cgt aac tct ggt gaa ggg gcc
Sample 
January 
29, 2016
I E T Y N F S N D Y I Y I R N S G E G A
att gaa aca tac aat ttt agt aat gat tat aat tat aat cgt aac tct ggt gaa ggg gcc
Pfcrt and Pfmdr1 genes point mutations are associated with quinoline (including amodiaquine) drug resistance; Pfdhfr and Pfdhps genes mutations are responsible for 
P. falciparum resistance to antifolate-cycloguanil; Pfk13 gene mutation C580Y is considered an important determinant of artemisinin resistance
Mutant codons from the three different samples are in blue
both pathogen- and host-related factors could have been 
responsible for the second recrudescence.
Based on the multidrug resistance pattern of P. falci-
parum, a complicated clinical course could have been 
expected. However, with the exception of a single blood 
transfusion, the patient did not require any extraordi-
nary therapeutic measure. Thalassaemia trait probably 
played a relevant role in attenuating the severity of the 
disease, whereas the clinical impact of dual infection 
was unclear, based on the heterogeneous results of sev-
eral studies regarding the mutual interactions between 
the two Plasmodium species and the role of immunity 
[15].
As Cambodia is known to be the cradle of anti-malarial 
drug resistance, patients returning from this area should 
be considered at risk for failure of artemisinin-based reg-
imens [16]. Therefore, according to our experience, even 
the most up-to-date guidelines should be handled with 
care in this rapidly evolving scenario and to this regard, 
the atovaquone/proguanil combination may be consid-
ered as a valuable therapeutic option in some special 
cases [17].
In a context of increasing international travel and 
trades in which exotic regions are easier to reach, the rel-
evance of a proper prophylaxis should be highlighted in 
order to obtain individual protection. Moreover, in this 
framework, an increased awareness about the possibility 
to manage such difficult cases also in non-endemic set-
tings should become a matter of utmost importance.
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